Neuroprotective effects of high affinity sigma 1 receptor selective compounds

[1]  B. Jarrott,et al.  Sigma-1 receptor ligand PRE-084 reduced infarct volume, neurological deficits, pro-inflammatory cytokines and enhanced anti-inflammatory cytokines after embolic stroke in rats , 2011, Brain Research Bulletin.

[2]  Teruo Hayashi,et al.  Targeting ligand-operated chaperone sigma-1 receptors in the treatment of neuropsychiatric disorders , 2011, Expert opinion on therapeutic targets.

[3]  H. Toresson,et al.  The sigma-1 receptor enhances brain plasticity and functional recovery after experimental stroke. , 2011, Brain : a journal of neurology.

[4]  C. Downes,et al.  The σ1 receptor agonist 4-PPBP elicits ERK1/2 phosphorylation in primary neurons: A possible mechanism of neuroprotective action , 2010, Neuropharmacology.

[5]  T. Mavlyutov,et al.  The sigma-1 receptor is enriched in postsynaptic sites of C-terminals in mouse motoneurons. An anatomical and behavioral study , 2010, Neuroscience.

[6]  J. Galvin,et al.  Potential future neuroprotective therapies for neurodegenerative disorders and stroke. , 2010, Clinics in geriatric medicine.

[7]  M. Kudo,et al.  SA4503, a sigma-1 receptor agonist, prevents cultured cortical neurons from oxidative stress-induced cell death via suppression of MAPK pathway activation and glutamate receptor expression , 2010, Neuroscience Letters.

[8]  Tangui Maurice,et al.  The pharmacology of sigma-1 receptors. , 2009, Pharmacology & therapeutics.

[9]  E. Arena,et al.  Anti‐amnesic properties of (±)‐PPCC, a novel sigma receptor ligand, on cognitive dysfunction induced by selective cholinergic lesion in rats , 2009, Journal of neurochemistry.

[10]  Sarah L Parylak,et al.  Sigma-1 receptor knockout mice display a depressive-like phenotype , 2009, Behavioural Brain Research.

[11]  J. Entrena,et al.  Pharmacology and Therapeutic Potential of Sigma1 Receptor Ligands , 2008, Current neuropharmacology.

[12]  T. Yorio,et al.  sigma-1 receptors protect RGC-5 cells from apoptosis by regulating intracellular calcium, Bax levels, and caspase-3 activation. , 2008, Investigative ophthalmology & visual science.

[13]  J. Simpkins,et al.  A prototypical Sigma-1 receptor antagonist protects against brain ischemia , 2007, Brain Research.

[14]  Teruo Hayashi,et al.  Sigma-1 Receptor Chaperones at the ER- Mitochondrion Interface Regulate Ca2+ Signaling and Cell Survival , 2007, Cell.

[15]  R. Mach,et al.  Fluorine-18-labeled benzamide analogues for imaging the sigma2 receptor status of solid tumors with positron emission tomography. , 2007, Journal of medicinal chemistry.

[16]  Sufang Yang,et al.  Sigma Receptor Agonists Provide Neuroprotection In Vitro by Preserving bcl-2 , 2007, Anesthesia and analgesia.

[17]  M. Elstner,et al.  Glutamate-induced cell death in neuronal HT22 cells is attenuated by extracts from St. John's wort (Hypericum perforatum L.). , 2007, Phytomedicine : international journal of phytotherapy and phytopharmacology.

[18]  T. Hupp,et al.  HIF-1α contributes to tumour-selective killing by the sigma receptor antagonist rimcazole , 2007, Oncogene.

[19]  L. Tankó,et al.  Matrix metalloproteinase and aggrecanase generated aggrecan fragments: implications for the diagnostics and therapeutics of destructive joint diseases , 2007 .

[20]  R. Mach,et al.  Synthesis of N-substituted 9-azabicyclo[3.3.1]nonan-3α-yl carbamate analogs as σ2 receptor ligands , 2006 .

[21]  Robert H Mach,et al.  Synthesis and characterization of selective dopamine D2 receptor antagonists. , 2006, Bioorganic & medicinal chemistry.

[22]  J. Simpkins,et al.  Neuroprotective effects of estratriene analogs: structure‐activity relationships and molecular optimization , 2005 .

[23]  R. Mach,et al.  Carbon-11 labeled σ2 receptor ligands for imaging breast cancer , 2005 .

[24]  R. Mach,et al.  [3H]N-[4-(3,4-dihydro-6,7-dimethoxyisoquinolin-2(1H)-yl)butyl]-2-methoxy-5-methylbenzamide: a novel sigma-2 receptor probe. , 2005, European journal of pharmacology.

[25]  J. Simpkins,et al.  Estrogens as protectants of the neurovascular unit against ischemic stroke. , 2005, Current drug targets. CNS and neurological disorders.

[26]  J. Simpkins,et al.  Neuroprotective effects of an estratriene analog are estrogen receptor independent in vitro and in vivo , 2005, Brain Research.

[27]  L. Montoliu,et al.  Formalin-induced pain is reduced in σ1 receptor knockout mice , 2005 .

[28]  A. Prescott,et al.  Small Molecule Antagonists of the σ-1 Receptor Cause Selective Release of the Death Program in Tumor and Self-Reliant Cells and Inhibit Tumor Growth in Vitro and in Vivo , 2004, Cancer Research.

[29]  X. Codony,et al.  Sigma receptors: biology and therapeutic potential , 2004, Psychopharmacology.

[30]  A. Schapira,et al.  Neuroprotection in Parkinson disease: mysteries, myths, and misconceptions. , 2004, JAMA.

[31]  R. Mach,et al.  Conformationally-flexible benzamide analogues as dopamine D3 and σ2 receptor ligands , 2004 .

[32]  D. Zamanillo,et al.  Generation and phenotypic analysis of sigma receptor type I (σ1) knockout mice , 2003 .

[33]  Teruo Hayashi,et al.  Understanding the molecular mechanism of sigma-1 receptors: towards a hypothesis that sigma-1 receptors are intracellular amplifiers for signal transduction. , 2003, Current medicinal chemistry.

[34]  Megan Lerner,et al.  σ Receptors: potential medications development target for anti-cocaine agents , 2003 .

[35]  R. Koehler,et al.  Potent sigma 1-receptor ligand 4-phenyl-1-(4-phenylbutyl) piperidine provides ischemic neuroprotection without altering dopamine accumulation in vivo in rats. , 2003, Anesthesia and analgesia.

[36]  L. Monassier,et al.  Sigma receptors: from discovery to highlights of their implications in the cardiovascular system , 2002, Fundamental & clinical pharmacology.

[37]  R. Mach,et al.  Characterization of 125I‐IABN, a novel azabicyclononane benzamide selective for D2‐like dopamine receptors , 2000, Synapse.

[38]  W. Bowen,et al.  Modulation of cellular calcium by sigma-2 receptors: release from intracellular stores in human SK-N-SH neuroblastoma cells. , 2000, The Journal of pharmacology and experimental therapeutics.

[39]  Y. Sagara,et al.  The Activation of Metabotropic Glutamate Receptors Protects Nerve Cells from Oxidative Stress , 1998, The Journal of Neuroscience.

[40]  P. Maher,et al.  Oxidative Stress Induces a Form of Programmed Cell Death with Characteristics of Both Apoptosis and Necrosis in Neuronal Cells , 1998, Journal of neurochemistry.

[41]  T. Maurice,et al.  Neuroprotective and anti-amnesic potentials of sigma (σ) receptor ligands , 1997, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[42]  E. Kempner,et al.  Purification, molecular cloning, and expression of the mammalian sigma1-binding site. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[43]  R. McBurney,et al.  In vitro neuroprotection by substituted guanidines with varying affinities for the N-methyl-D-aspartate receptor ionophore and for sigma sites. , 1994, Journal of Pharmacology and Experimental Therapeutics.

[44]  T. Murphy,et al.  Glutamate toxicity in a neuronal cell line involves inhibition of cystine transport leading to oxidative stress , 1989, Neuron.

[45]  E. London,et al.  Correlation of inhibitory potencies of putative antagonists for σ receptors in brain and spleen , 1988 .

[46]  T. Su.  Evidence for sigma opioid receptor: binding of [3H]SKF-10047 to etorphine-inaccessible sites in guinea-pig brain. , 1982, The Journal of pharmacology and experimental therapeutics.

[47]  Y. Cheng,et al.  Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. , 1973, Biochemical pharmacology.

[48]  A. Marrazzo,et al.  Anti-amnesic and neuroprotective actions of the sigma-1 receptor agonist (-)-MR22 in rats with selective cholinergic lesion and amyloid infusion. , 2011, Journal of Alzheimer's disease : JAD.

[49]  R. Hotchkiss,et al.  Identification of the PGRMC1 protein complex as the putative sigma-2 receptor binding site. , 2011, Nature communications.

[50]  Teruo Hayashi,et al.  Sigma-1 receptor chaperones at the ER-mitochondrion interface regulate Ca(2+) signaling and cell survival. , 2007, Cell.

[51]  L. Montoliu,et al.  Formalin-induced pain is reduced in sigma(1) receptor knockout mice. , 2005, European journal of pharmacology.

[52]  R. Mach,et al.  Conformationally-flexible benzamide analogues as dopamine D3 and sigma 2 receptor ligands. , 2004, Bioorganic & medicinal chemistry letters.

[53]  D. Zamanillo,et al.  Generation and phenotypic analysis of sigma receptor type I (sigma 1) knockout mice. , 2003, The European journal of neuroscience.

[54]  R. Mach,et al.  Synthesis of n-substituted 9-azabicyclo[3.3.1]nonan-3α-yl phenylcarbamate analogs as sigma-2 receptor ligands , 2002 .

[55]  M. Groves.  Hypericum perforatum L. , 1998 .

[56]  R. Mach,et al.  Synthesis and quantitative structure-activity relationships of N-(1-benzylpiperidin-4-yl)phenylacetamides and related analogues as potent and selective sigma1 receptor ligands. , 1998, Journal of medicinal chemistry.

[57]  T. Maurice,et al.  Neuroprotective and anti-amnesic potentials of sigma (sigma) receptor ligands. , 1997, Progress in neuro-psychopharmacology & biological psychiatry.

[58]  T. Su,et al.  Steroid binding at sigma receptors: CNS and immunological implications. , 1990, Ciba Foundation symposium.

[59]  E. London,et al.  Correlation of inhibitory potencies of putative antagonists for sigma receptors in brain and spleen. , 1988, European journal of pharmacology.